High expression of aldolase B confers a poor prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

Yu Feng Tian, Pei Ling Hsieh, Ching Yih Lin, Ding Ping Sun, Ming Jen Sheu, Ching Chieh Yang, Li Ching Lin, Hong Lin He, Julia Solórzano, Chien Feng Li, I. Wei Chang

研究成果: 雜誌貢獻文章

4 引文 斯高帕斯(Scopus)

摘要

Background: Colorectal cancer is the third most common cancer in both sex worldwide and it is also the fourth most common cause of cancer mortality. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer. By data mining a documented database of rectal cancer transcriptome (GSE35452) from Gene Expression Omnibus, National Center of Biotechnology Information, we recognized that ALDOB was the most significantly up-regulated transcript among those related to glycolysis (GO: 0006096). Hence, we analyzed the clinicopathological correlation and prognostic effect of ALDOB protein (Aldolase B), which encoded by ALDOB gene.Methods: ALDOB immunostain was performed in 172 rectal adenocarcinomas treated with preoperative chemoradiotherapy followed by radical surgery, which were divided into high- and low-expression groups. Furthermore, statistical analyses were examined to correlate the relationship between ALDOB immunoreactivity and important clinical and pathological characteristics, as well as three survival indices: disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS). Results: ALDOB (Aldolase B) over-expression was significantly associated with pre-CCRT and post-CCRT tumor advancement, lymphovascular invasion, perineural invasion and poor response to CCRT (all P = .023). In addition, ALDOB high expression was linked to adverse DSS, LRFS and MeFS in univariate analysis (P = .0075) and also served as an independent prognosticator indicating dismal DSS and MeFS in multivariate analysis (hazard ratio (HR) = 3.462, 95% confidence interval (CI): 1.263-9.495; HR = 2.846, 95% CI: 1.190-6.808, respectively).Conclusion: ALDOB (Aldolase B) may play an imperative role in rectal cancer progression and responsiveness to neoadjuvant CCRT, and serve as a novel prognostic biomarker. Additional researches to clarify the molecular and biochemical pathways are essential for developing promising ALDOB-targeted therapies for patients with rectal cancers.
原文英語
頁(從 - 到)1197-1204
頁數8
期刊Journal of Cancer
8
發行號7
DOIs
出版狀態已發佈 - 四月 9 2017
對外發佈Yes

ASJC Scopus subject areas

  • Oncology

指紋 深入研究「High expression of aldolase B confers a poor prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy」主題。共同形成了獨特的指紋。

  • 引用此

    Tian, Y. F., Hsieh, P. L., Lin, C. Y., Sun, D. P., Sheu, M. J., Yang, C. C., Lin, L. C., He, H. L., Solórzano, J., Li, C. F., & Chang, I. W. (2017). High expression of aldolase B confers a poor prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Journal of Cancer, 8(7), 1197-1204. https://doi.org/10.7150/jca.18197